Acute Bronchitis, Acute Exacerbations of Chronic Bronchitis
Conditions
Keywords
acute bronchitis, acute exacerbations of chronic bronchitis
Brief summary
The purpose of this study is to determine the optimal dose of HL301 in patients with acute bronchitis or acute exacerbations of chronic bronchitis. \- BSS(Bronchitis Severity Score), BCSS(Breathlessness, Cough, and Sputum Scale), evaluation of symptoms of cough and sputum
Interventions
DRUGHL301 300mg capsule
2 capsules at once, 3 times a day, for 7 days
DRUGPlacebo
2 capsules at once, 3 times a day, for 7 days
Sponsors
Hanlim Pharm. Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Both gender, 19 years ≤ age ≤ 80 years 2. Acute bronchitis or acute exacerbations of chronic bronchitis patients with BSS(Bronchitis Severity Score)\* ≥ 5point at Visit1 and Visit2 3. Written consent voluntarily to participate in this clinical trial
Exclusion criteria
1. Patients who were increased the bleeding tendency 2. Patients with any of Alanine aminotransferase, Aspartate aminotransferase or serum Blood Urea Nitrogen, Creatinine\> 2 times of the normal upper range 3. Patients who investigators determines to severe respiratory disease that would interfere with study assessment 4. Patients with COPD(Chronic Obstructive Pulmonary Disease) history of stage 3 or more 5. Patients who were treated with oral systemic adrenocortical hormone or immunosuppressive drug within 4 weeks prior to study participation 6. Patients who were treated with oral β2-agonist, anticholinergic, Methylxanthine, antibiotics, antihistamines, sympathomimetic agent or oriental medicine/health functional food for antitussive and mucolytic Effect within 1 weeks prior to study participation 7. Patients who were treated with oral Antitussive, Mucolytic Agents,systemic antimicrobial agent within 3 days prior to study medication dosing 8. Patients with drug or alcohol abuse 9. Patients with clinically significant active liver, renal, cardiovascular, respiratory, endocrine, central nervous system disease or history of malignant tumor or mental illness(except no relapse for 5 years after surgery) 10. The aged person with severe medical history which is mental disorder(dementia), cancer, chronic renal failure, chronic liver failure 11. Pregnant or breast-feeding 12. Patients currently participating in or has participated in other clinical study within 30 days prior to study participation 13. Patients who investigators determines not appropriate to take part in this clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bronchitis Severity Score | baseline(day 0) and day 7 | Bronchitis Severity Score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Breathlessness, Cough, and Sputum Scale | baseline(day 0) and day 7 | Breathlessness, Cough, and Sputum Scale |
| evaluation of symptoms of cough and sputum | baseline(day 0) and day 7 | — |
| Total usage of acetaminophen | baseline(day 0) and day 7 | — |
Countries
South Korea
Outcome results
None listed